Non-Hodgkin's lymphoma Cancer Non-Hodgkin's lymphoma
Conditions
Interventions
Patients are randomised to one of three treatment regimens:
1. Regimen A: Radiotherapy 40 Gy in twenty to twenty-five fractions.
2. Regimen B: Chemotherapy with cylopho
Sponsors
Cancer Research UK (CRUK) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Biopsy-proven non-Hodgkin's lymphoma of any of the following histologies: International Working Formulation groups F, G and H; Kiel Classification: centroblastic B-cell, pleomorphic medium and large T-cell, immunoblastic, large cell anaplastic and high grade unclassified; Revised European-American Classification of Lymphoid Neoplasms (REAL Classification): Diffuse large B-cell, anaplastic large cell, high-grade B-cell or Mucosa-associated lymphoid tissue (MALT) type, and peripheral T-cell 2. WHO performance status 0, 1, 2 3. Aged greater than 15 years 4. No previous chemotherapy or radiotherapy 5. Normal lactic dehydrogenase (LDH) 6. Stage I, IE, II, IIE, except bulky abdominal presentation 7. No B symptoms 8. No previous malignancy, except basal cell carcinoma of the skin or cervical carcinoma stage I 9. No evidence of Human Immunodeficiency Virus (HIV) positively 10. No contraindications to protocol treatments
Exclusion criteria
Exclusion criteria: Patients with testicular, brain, gastrointestinal or skin primaries are excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed